Vor Biopharma Inc.
Vor Biopharma Inc. (VOR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
vor · stock forecast · 13 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$46.00
Consensus
$31.67
+138.3% upside
Low
$18.00
Median: $31 · Last Close: $13.29
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$31.67
138.3% upside
High Target
$46
246.1%
Low Target
$18
35.4%
Current Price
$13.29
as of today
Based on analyst price targets, the VOR stock price prediction for the next 12 months ranges from $18 to $46. The consensus VOR price forecast of $31.67 implies 138.3% upside from the current price of $13.29.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $12.67 | ↓ 4.64% |
1-day model range: $12.41–$12.94. Peak: $12.94 (-4.64%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · VOR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-14 | Wedbush | Maintains | Neutral→Neutral |
| 2026-04-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-31 | Wedbush | Maintains | Neutral→Neutral |
| 2025-12-19 | JP Morgan | Maintains | Overweight→Overweight |
| 2025-11-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-15 | Baird | Upgrade ↑ | Neutral→Outperform |
| 2025-08-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-30 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
Wall Street analysts have recently issued updated ratings on Vor Biopharma Inc. (VOR) stock. Of the recent 67 rating actions, 2 were upgrades and 2 were downgrades. 13 analysts currently cover VOR.
Analyst Recommendation Trends
VOR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4M
↓ 85.6% YoY
Revenue Next Year
$10M
↑ 140.0% YoY
EPS This Year
$-6.50
EPS Next Year
$-3.48
↓ 46.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast VOR EPS of $-6.50 for the current fiscal year, based on estimates from 5 analysts. The VOR revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The VOR stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VOR price target is $31.67 (+138.3% upside), with an analyst consensus of Buy.
The VOR short-term stock prediction for tomorrow is $12.67 (-4.64%).
Vor Biopharma Inc. trades on NASDAQ under the ticker VOR. The VOR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 77% of covering analysts.
Frequently asked questions
VOR forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month VOR price target is $31.67, with a high forecast of $46.00 and a low of $18.00. The median price target is shown in the chart above when available. This implies +138.3% potential upside from the current price of $13.29.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.